Skip to main content

Leukaemia: Drugs

Volume 472: debated on Tuesday 26 February 2008

To ask the Secretary of State for Health whether the South West Surrey and Hampshire Cancer Network recommends Dasatinib for the treatment of imatinib-resistant chronic myeloid leukaemia. (186265)

Dasatinib has been licensed for the treatment of chronic myeloid leukaemia (CML) with resistance or intolerance to imatinib mesylate. The National Institute for Health and Clinical Excellence (NICE) has not yet published guidance on the use of Dasatinib. Until NICE guidance is published, it is for primary care trusts (PCTs) to make decisions based on the evidence that is available on whether to fund drugs locally.

South East Coast strategic health authority has advised officials that Surrey, West Sussex and Hampshire Cancer Network has not produced any formal recommendations on the use of Dasatinib. It does, however, provide advice and recommendations to PCTs on an individual patient basis when requested to do so.